Related references
Note: Only part of the references are listed.A method for measuring glycerol-blanked triglyceride concentrations by using gas chromatography-isotope dilution mass spectrometry
Isao Koyama et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2020)
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Oxidized Lipoprotein Levels: A Case Report
Kazuhiko Kotani et al.
JOURNAL OF APPLIED LABORATORY MEDICINE (2020)
Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese
Tomoyuki Tajima et al.
SCIENTIFIC REPORTS (2018)
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017
Makoto Kinoshita et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2018)
Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hyper-cholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation
Ryo Shirahama et al.
INTERNAL MEDICINE (2018)
Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease
Hayato Tada et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Triglyceride concentrations should be measured after elimination of free glycerol to exclude interindividual variations due to adiposity and fasting status
Terumichi Nakagawa et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2017)
ClinVar: public archive of interpretations of clinically relevant variants
Melissa J. Landrum et al.
NUCLEIC ACIDS RESEARCH (2016)
Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia
Thomas Grenkowitz et al.
ATHEROSCLEROSIS (2016)
Familial Hypercholesterolemia in Asian Populations
Mengge Zhou et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2016)
Proprotein convertase subtilisin/kexin 9 V41 variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia
Naotaka Ohta et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2016)
Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population
Christel H. Kamani et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2015)
The contribution of PCSK9 levels to the phenotypic severity of familial hypercholesterolemia is independent of LDL receptor genotype
Jean-Philippe Drouin-Chartier et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2015)
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation
Hiroshi Mabuchi et al.
ATHEROSCLEROSIS (2014)
Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
Naif A. M. Almontashiri et al.
PLOS ONE (2014)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High-Dose Statin Therapy
Frederick Raal et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome
Caroline Richard et al.
BRITISH JOURNAL OF NUTRITION (2012)
Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
Zuhier Awan et al.
CLINICAL CHEMISTRY (2012)
Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells
Seyed A. Mousavi et al.
FEBS JOURNAL (2011)
A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
Taichi Yamamoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
Lena Persson et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Increased Secretion of Lipoproteins in Transgenic Mice Expressing Human D374Y PCSK9 Under Physiological Genetic Control
Bronwen Herbert et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation
Tohru Noguchi et al.
ATHEROSCLEROSIS (2010)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Greg Welder et al.
JOURNAL OF LIPID RESEARCH (2010)
Preparation of DNA Ladder Based on Multiplex PCR Technique
Tian-Yun Wang et al.
JOURNAL OF NUCLEIC ACIDS (2010)
Molecular basis of PCSK9 function
Gilles Lambert et al.
ATHEROSCLEROSIS (2009)
PCSK9 as a therapeutic target of dyslipidemia
Nabil G. Seidah
EXPERT OPINION ON THERAPEUTIC TARGETS (2009)
Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
Hai Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree
KM Timms et al.
HUMAN GENETICS (2004)
Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9
K Ouguerram et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
